title: Altered WAF1 genes do not play a role in abnormal cell cycle regulation in breast cancers lacking p53 mutations.
abstract: Seventy-five to 80% of breast cancers are negative for p53 gene mutations. We have investigated the possibility that altered WAF1 genes provide an alternative mode of cell cycle disruption in these tumors. DNA from a total of 85 primary breast tumors and cell lines from both the United States and Australia were examined for WAF1 and p53 mutations. With the exception of one primary tumor containing the polymorphic codon 31 (AGC-->AGA), no missense mutations in the WAF1 gene were found in 33 primary tumors or in the 19 cell lines from the United States. By contrast, 2 of 33 tumors from Australia contained tumor-specific missense mutations in the WAF1 gene, while an additional six cases contained the AGC-->AGA polymorphic 31st codon in the WAF1 gene. The p53 mutation frequency in the Australian cohort (18%) was found to be similar to that reported by us (Glebov et al., Cancer Res., 54: 3703-3709, 1994; Runnebaum et al., Proc. Natl. Acad. Sci. USA, 88: 10657-10661, 1991) in the tumors of United States patients (13%) with sporadic breast cancer. Thus, mutations in the WAF1 gene are rare in tumors with or without p53 mutations, suggesting that except in a minor population of breast cancer patients of Caucasian origin, cell cycle dysregulation by mutated p53 or WAF1 genes may not contribute to breast tumor initiation or progression.
authors.affiliation: Breast Cancer Program, Johns Hopkins Oncology Center, Baltimore, Maryland 21045, USA.
authors.forename: K E
authors.initials: KE
authors.lastname: McKenzie
authors.forename: A
authors.initials: A
authors.lastname: Siva
authors.forename: S
authors.initials: S
authors.lastname: Maier
authors.forename: I B
authors.initials: IB
authors.lastname: Runnebaum
authors.forename: R
authors.initials: R
authors.lastname: Seshadri
authors.forename: S
authors.initials: S
authors.lastname: Sukumar
mesh_terms: D001315:Australia; D001943:Breast Neoplasms / Q000235:genetics* / Q000473:pathology; D002453:Cell Cycle / Q000235:genetics; D003001:Cloning, Molecular; D003062:Codon / Q000235:genetics; D050759:Cyclin-Dependent Kinase Inhibitor p21; D016213:Cyclins / Q000235:genetics*; D004252:DNA Mutational Analysis; D004273:DNA, Neoplasm / Q000235:genetics*; D005260:Female; D016158:Genes, p53; D006801:Humans; D017354:Point Mutation; D012150:Polymorphism, Restriction Fragment Length; D018807:Polymorphism, Single-Stranded Conformational; D017422:Sequence Analysis, DNA; D014407:Tumor Cells, Cultured; D014481:United States
chemical_list: C493956:CDKN1A protein, human; D003062:Codon; D050759:Cyclin-Dependent Kinase Inhibitor p21; D016213:Cyclins; D004273:DNA, Neoplasm